SCHOTT Pharma KGaA Second Quarter 2025 Earnings: EPS Beats Expectations

SCHOTT Pharma KGaA (ETR:1SXP) Second Quarter 2025 Results

Key Financial Results

• Revenue: €252.3m (up 7.7% from 2Q 2024).
• Net income: €38.4m (up 54% from 2Q 2024).
• Profit margin: 15% (up from 11% in 2Q 2024). The increase in margin was driven by higher revenue.
• EPS: €0.26 (up from €0.17 in 2Q 2024).

We check all companies for important risks. See what we found for SCHOTT Pharma KGaA in our free report.

All figures shown in the chart above are for the trailing 12 month (TTM) period

SCHOTT Pharma KGaA EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%.

Looking ahead, revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.

Performance of the market in Germany.

The company's shares are up 4.0% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of SCHOTT Pharma KGaA's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.